Cargando…

Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRAS(G12C)

Special oncogenic mutations in the RAS proteins lead to the aberrant activation of RAS and its downstream signaling pathways. AMG510, the first approval drug for KRAS, covalently binds to the mutated cysteine 12 of KRAS(G12C) protein and has shown promising antitumor activity in clinical trials. Rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhuang, Haiming, Fan, Jigang, Li, Mingyu, Zhang, Hao, Yang, Xiuyan, Lin, Ligen, Lu, Shaoyong, Wang, Qing, Liu, Yaqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399772/ https://www.ncbi.nlm.nih.gov/pubmed/36033504 http://dx.doi.org/10.3389/fonc.2022.915512

Ejemplares similares

Understanding the influence of AMG 510 on the structure of KRAS(G12C) empowered by molecular dynamics simulation
por: Li, Yu, et al.
Publicado: (2022)

KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations
por: Pantsar, Tatu
Publicado: (2020)

Spotlight on Sotorasib (AMG 510) for KRAS(G12C) Positive Non-Small Cell Lung Cancer
por: Zhang, Shannon S, et al.
Publicado: (2021)

CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
por: Brazel, Danielle, et al.
Publicado: (2023)

AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research
por: Wu, Lei-Lei, et al.
Publicado: (2023)

Mechanistic Insights into the Protection Effect of Argonaute–RNA Complex on the HCV Genome
por: Zhuang, Haiming, et al.
Publicado: (2022)

Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG-510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCL-XL
por: Kitazawa, Masato, et al.
Publicado: (2021)

Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
por: Wang, Yini, et al.
Publicado: (2023)

Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells
por: Padmanabhan, Jaya, et al.
Publicado: (2021)

Evaluation of AMG510 Therapy on KRAS-Mutant Non–Small Cell Lung Cancer and Colorectal Cancer Cell Using a 3D Invasive Tumor Spheroid System under Normoxia and Hypoxia
por: Huang, Meng, et al.
Publicado: (2022)

Toward Soluble 5,10-Diheterotruxenes: Synthesis and Reactivity of 5,10-Dioxatruxenes, 5,10-Dithiatruxenes, and 5,10-Diazatruxenes
por: Górski, Krzysztof, et al.
Publicado: (2020)

Delineating the activation mechanism and conformational landscape of a class B G protein-coupled receptor glucagon receptor
por: Wang, Ying, et al.
Publicado: (2022)

Molecular Characterization of Acquired Resistance to KRAS(G12C)–EGFR Inhibition in Colorectal Cancer
por: Yaeger, Rona, et al.
Publicado: (2023)

Combined KRAS(G12C) and SOS1 inhibition enhances and extends the anti-tumor response in KRAS(G12C)-driven cancers by addressing intrinsic and acquired resistance
por: Thatikonda, Venu, et al.
Publicado: (2023)

Mechanistic Elucidation of Activation/Deactivation Signal Transduction within Neurotensin Receptor 1 Triggered by ‘Driver Chemical Groups’ of Modulators: A Comparative Molecular Dynamics Simulation
por: Lu, Xun, et al.
Publicado: (2023)

Imidazo[1,2-b]isoquinoline-5,10-dione
por: N. Al-Mohammed, Nassir, et al.
Publicado: (2011)

Mechanistic insights into the effect of phosphorylation on Ras conformational dynamics and its interactions with cell signaling proteins
por: Wang, Yuanhao, et al.
Publicado: (2021)

Elucidation of the conformational dynamics and assembly of Argonaute–RNA complexes by distinct yet coordinated actions of the supplementary microRNA
por: Zhuang, Haiming, et al.
Publicado: (2022)

Evolution of acquired resistance in a ROS1(+) KRAS G12C(+) NSCLC through the MAPK pathway
por: Priest, Katherine, et al.
Publicado: (2023)

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy
por: Ryan, Meagan B., et al.
Publicado: (2022)

Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
por: Mohanty, Atish, et al.
Publicado: (2023)

Mechanisms of Resistance to KRAS(G12C) Inhibitors
por: Dunnett-Kane, Victoria, et al.
Publicado: (2021)

Comparison of AMG 416 and cinacalcet in rodent models of uremia
por: Walter, Sarah, et al.
Publicado: (2014)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

Autopromotion of K-Ras4B Feedback Activation Through an SOS-Mediated Long-Range Allosteric Effect
por: He, Xuan, et al.
Publicado: (2022)

2-Amino-4-(2-chlorophenyl)-5,10-dioxo-5,10-dihydro-4H-benzo[g]chromene-3-carbonitrile
por: Zhang, Jinpeng, et al.
Publicado: (2008)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

Targeting KRAS G12C mutations in colorectal cancer
por: Zhao, Ming-He, et al.
Publicado: (2022)

Bcl-xL Is a Key Mediator of Apoptosis Following KRAS(G12C) Inhibition in KRAS(G12C)-mutant Colorectal Cancer
por: Khawaja, Hajrah, et al.
Publicado: (2023)

Evaluation of the Olympus AU-510 analyser
por: Farré, Carmen, et al.
Publicado: (1991)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

Ethyl 2-amino-4-(3-chlorophenyl)-5,10-dioxo-5,10-dihydro-4H-benzo[g]chromene-3-carboxylate
por: Hu, Xiao, et al.
Publicado: (2009)

Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
por: Chen, Chih-Chieh, et al.
Publicado: (2013)

Overcoming Resistance to Drugs Targeting KRAS(G12C) Mutation
por: Jiao, Delong, et al.
Publicado: (2020)

Searching for treatments for non-G12C-KRAS mutant cancers
por: Guo, Christina, et al.
Publicado: (2021)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

The Research Progress of Direct KRAS G12C Mutation Inhibitors
por: Yang, Ai, et al.
Publicado: (2021)

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

AAC - LEAR transfer efficiencies from 07/10/96 to 18/12/96
por: Sanchez Alvarez, José-Luis
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_dte7dn5pttkrg0u5fbk6ccfda9